One To Watch
Alector
Company Overview
A South San Francisco-based immuno-neurology biotech pioneering innate immune system modulation to treat neurodegenerative diseases including Alzheimer's disease and frontotemporal dementia. Alector's core thesis holds that harnessing and restoring microglial immune function can slow or halt neurodegeneration. The company has built a portfolio of antibody-based programs targeting innate immune pathways in the brain. After a series of high-profile clinical setbacks through 2024–2026, Alector is navigating a significant strategic reset.
Headquarters and Global Presence
Alector is headquartered in South San Francisco, California, positioning it within the Bay Area's dense biotech ecosystem. The company operates primarily from this single site, with global commercial rights for key programs historically managed through partnerships with GSK and AbbVie.
Founding and History
Alector was founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery, including co-founder and CEO Arnon Rosenthal. The company raised a $133 million Series E financing round and simultaneously revealed its first three programs targeting Alzheimer's disease and frontotemporal dementia. A landmark collaboration with GSK in 2021 valued at $700 million upfront elevated Alector's profile considerably. Subsequent clinical failures across multiple programs have fundamentally altered the company's trajectory and workforce size.
Therapy Areas and Focus
Alector focuses exclusively on neurodegenerative diseases, with Alzheimer's disease and frontotemporal dementia (FTD) forming the core of its clinical strategy. The company operates under the immuno-neurology framework — the hypothesis that dysfunctional microglial activity is a primary driver of neurodegeneration. FTD represents a particularly high unmet need, as it is a rare and aggressive dementia with no approved disease-modifying treatments. Alzheimer's disease remains one of the most commercially significant targets in medicine, despite the sector's high attrition rate.
Technology Platforms and Modalities
Alector's platform centers on monoclonal antibodies designed to modulate innate immune receptors expressed on microglia — the brain's resident immune cells. By targeting receptors such as TREM2 and PILRA, Alector aims to restore microglial function and reduce neuroinflammation-driven damage. This immuno-neurology approach is mechanistically distinct from amyloid- or tau-targeting strategies that dominate competitor pipelines. The antibody discovery expertise embedded at founding underpins the company's ability to generate candidates against difficult CNS immune targets.
Key Pipeline and Programs
Latozinemab (AL001) is a progranulin-elevating antibody targeting sortilin, designed to treat frontotemporal dementia caused by GRN mutations. The asset was partnered with GSK and advanced into Phase III development. In October 2025, however, the Phase III trial failed to meet its primary clinical endpoint, triggering a 49% workforce reduction and the effective dissolution of the GSK collaboration.
Nivisnebart was Alector's Alzheimer's candidate developed in partnership with GSK, evaluated in the Phase II PROGRESS-AD trial. An interim analysis reported in May 2026 indicated the trial was unlikely to meet its primary endpoint, leading to discontinuation of the program and formally ending the GSK partnership.
AL002 is a TREM2-targeting agonist antibody intended to enhance microglial function in early Alzheimer's disease. The INVOKE-2 Phase II trial reading out in November 2024 missed its primary goal, sending shares down 35%. AL008, an immuno-oncology candidate, was out-licensed to Innovent Biologics for development and commercialization in China in June 2024.
Recent Developments
In May 2026, Alector discontinued nivisnebart following a failed interim analysis in the PROGRESS-AD Phase II Alzheimer's trial, ending its collaboration with GSK entirely. This followed the October 2025 Phase III failure of latozinemab in FTD, which caused shares to fall more than 50% and prompted a 49% staff reduction. The November 2024 INVOKE-2 Phase II miss for AL002 had preceded both events, establishing a difficult run of readouts across the portfolio. AbbVie also withdrew from its Alzheimer's collaboration with Alector in June 2024, compounding the company's strategic challenges.
Key Personnel
Arnon Rosenthal serves as Co-Founder and CEO, bringing deep expertise in neuroscience and antibody drug discovery that was central to Alector's founding vision. Brian Sander serves as General Counsel, overseeing legal and regulatory affairs as the company restructures. Clare Hunt serves as Chief People Officer, a role of particular significance given the company's 49% workforce reduction in late 2025.
Strategic Partnerships
Alector's most significant collaboration was with GSK, which paid $700 million upfront in 2021 to co-develop latozinemab and nivisnebart; both programs have now been discontinued. AbbVie had entered a $205 million Alzheimer's research deal with Alector but withdrew from the collaboration in June 2024. Alector out-licensed Chinese rights to AL008 to Innovent Biologics in June 2024 under a regional licensing agreement covering oncology indications.
FAQ Section
Alector bets that restoring microglial immune function — rather than clearing amyloid or tau directly — can slow neurodegeneration at a more fundamental level. Microglia are the brain's resident immune cells, and Alector's antibodies aim to modulate receptors like TREM2 and sortilin to reinstate healthy immune surveillance. This stands apart from the amyloid-clearance strategies pursued by Biogen, Eisai, and Eli Lilly.
AL002, designed as an agonist antibody to enhance TREM2-mediated microglial activity, missed its primary endpoint in the Phase II INVOKE-2 trial evaluating disease progression in early Alzheimer's patients. The November 2024 readout sent shares down 35% to $2.57. The failure raised broader questions about whether TREM2 agonism alone can produce measurable clinical benefit in the Alzheimer's disease context.
GSK paid $700 million upfront in 2021 to co-develop two Alector assets — latozinemab in FTD and nivisnebart in Alzheimer's. Both programs failed clinically: latozinemab's Phase III readout in October 2025 missed its endpoint, and nivisnebart's Phase II PROGRESS-AD interim was discontinued in May 2026. TD Cowen analysts characterized the second failure as effectively ending the GSK partnership, leaving Alector without its most significant commercial relationship.
Latozinemab (AL001) is a sortilin-targeting antibody designed to elevate progranulin levels in patients with GRN-mutation frontotemporal dementia — a rare, genetically defined population with no approved disease-modifying therapy. The genetic clarity of this patient population made it an attractive development target, as biomarker-driven patient selection was straightforward. Its Phase III failure in October 2025 was all the more striking given the scientific rationale and late-stage investment behind it.
Following the discontinuation of latozinemab, nivisnebart, and AL002, Alector's active clinical footprint has contracted sharply. AL008, an immuno-oncology candidate, was out-licensed to Innovent Biologics for China in June 2024, representing a pivot away from CNS for that asset. The company's remaining strategic direction beyond these programs has not been publicly detailed following its workforce reduction.
Alector entered 2024 as a late-stage clinical company with two Phase III-capable assets backed by a $700 million GSK deal. By mid-2026, both major partnered programs had been discontinued, AbbVie had exited its collaboration, and the company had cut nearly half its workforce. This repositions Alector as an early-to-mid-stage organization in active restructuring, with its next development chapter yet to be defined.
Investors and observers should monitor several critical factors as Alector regroups following its major clinical failures:
Latest Alector News
Today's issue
| Headless Content Management with Blaze